AU2001281786A1 - Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds - Google Patents
Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compoundsInfo
- Publication number
- AU2001281786A1 AU2001281786A1 AU2001281786A AU2001281786A AU2001281786A1 AU 2001281786 A1 AU2001281786 A1 AU 2001281786A1 AU 2001281786 A AU2001281786 A AU 2001281786A AU 2001281786 A AU2001281786 A AU 2001281786A AU 2001281786 A1 AU2001281786 A1 AU 2001281786A1
- Authority
- AU
- Australia
- Prior art keywords
- microemulsion
- biologically active
- surfactant
- active compound
- sustained release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS FOR THE PARENTERAL ADMINISTRATION OF BIOLOGICALLY ACTIVE HYDROPHILIC COMPOUNDS
Field of the invention
The present invention relates to sustained release pharmaceutical compositions for the parenteral administration of active ingredients which are hydrophilic or are made hydrophilic by suitable derivatization, in the form of stable, biologically compatible and easily preparable water-in-oil microemulsions (w/o). More particularly, peptide active ingredients or biologically active oligo- or polysaccharides, for which protection from the immediate attack by the hydrolytic enzymes present in living organisms as well as sustained release in time, to avoid repeated administrations, are desirable, are advantageously formulated through said microemulsions. Said formulations for the therapeutical use can be injected without problems or significant side effects and are easily prepared industrially, providing a remarkable technical improvement. Prior art Microemulsions can be generally defined as optically isotropic systems, not birifrangent under polarized light observation, transparent, thermodynamically stable, of extremely reduced size, with droplet diameter ranging from 5 to 200 nm, produced by dispersion of two immiscible liquids which are stabilized by the presence of emulsifiers, which modify the chemical-physical properties of the separation surface between the two liquids, reducing substantially to zero the interfacial tension. An oil, water, a surfactant or tenside and optionally of a co-surfactant o co-tenside should usually be present for microemulsions to form; the tendency to form a water-in-oil (w/o) or oil-in-water (o/w) microemulsion depends on the mutual proportions of
aqueous and oily phases as well as on the nature of the surfactant. In particular, ternary phase diagrams having as components water, a hydrophobic compound and a mixture of surfactant and co-surfactant, obtained according to experimental data, allow to single out the area in which w/o and o/w microemulsions exist and are stable. For example, Aboofazeli et al (Int.J.Pharm. I l l (1994) 63-72) studied the capability of various compounds having co-surfactant action to form w/o microemulsions. The system studied by the Authors consisted of mixtures of a fatty acid ester, a 1 :1 lecithin-co- surfactant and water in various ratios. An efficiency scale of the compounds used as co-surfactants has been defined: primary amines > alcohols> fatty acids. Furthermore, the efficiency proved to be related with the length of the alkyl chain of the alcohol and of the respective fatty acid; hence butanol>pentanol>hexanol> pentanoic acid>hexanoic acid. On the basis of these experimental data, alcohols such as butanol and pentanol and, to a less extent, the corresponding fatty acids, appear to be the best candidates. The use of the described compounds allows to prepare stable w/o microemulsions, but does not ensure the tolerability of said formulations, particularly for the depot use wherein the formulation and the subcutaneous or intramuscular tissue remain in contact for days or even weeks. Moreover, literature reports that the co-surfactant to surfactant ratio is critical; the data reported by Aboofazeli et al. relate to a 1 : 1 ratio between the two components. Atwood et al (Int.J.Pharmacy 84 R5 (1992)) studied the behaviour of lecithin/water/fatty acid ester/butanol mixtures wherein the surfactant/co-surfactant ratio is increased from about 1.7 to 3. The Authors evidenced that the decrease of the co-surfactant amount in favor of lecithin dramatically restricts the area in which the presence of a w/o microemulsion is observed, even when using a remarkably efficient co-surfactant such as butanol.
Surfactants are generally classified according to an empirical scale, known as hydrophile-lipophile balance (HLB) which assignee values ranging from 1 to 40. As a rule, suitable surfactants for w/o microemulsions have low HLB whereas those suitable for o/w microemulsions have high HLB. When the interfacial tension is <2 xl0~2 dyn/cm, a stable microemulsion can form. The optional presence of a co-surfactant allows to increase the interfacial fluidity, as the co-surfactant molecules penetrate between the surfactant molecules, thereby producing a dishomogeneous surface film. Co-surfactants can also decrease the aqueous phase hydrophilia and hence the interfacial tension between the two phases. In principle, the use of co-surfactants is advantageous in that they allow to decrease the amount of necessary surfactant while increasing the stability of the microemulsion; however, as already mentioned above, it is preferable to limit their use as they have potential topical toxicity, mainly in case of contact between the carrier and the subcutaneous or intramuscular tissues for prolonged times.
The numerous advantages of the use of a microemulsion as a carrier for active ingredients are known.
Microemulsions, under specific conditions of ratios between the components, can form spontaneously without need for high power for the preparation thereof; therefore their preparation on an industrial scale can be easy. Said spontaneous microemulsions are thermodynamically stable, homogeneous and transparent, so that they can be monitored by spectroscopical techniques. Microemulsions with mean diameters <100 nm can be prepared, which can be cold sterilized by filtration trough 0.22 micron membrane commercial filters. The microemulsions can allow to administer poorly soluble or poorly stable drugs.
Furthermore said systems can undergo phase inversion when an excess of the dispersed phase is present, or as a consequence of a change of
temperature: this property can affect the bioavailability of the active ingredient with a mechanism that has not yet been clarified.
The w/o microemulsions can control the release of the active ingredient or protract its stability in physiologic fluids through protection from the action of hydrolytic enzymes. A number of reviews on microemulsions exist, for example "Industrial application of microemulsions" Marcel Dekker Ed. 1997, which in the chapter "Microemulsions in the Pharmaceutical field: perspectives and applications" deals with the usefulness thereof in the pharmaceutical field, and "Handbook of Microemulsion Technology", Ed. Kumar Mittal (1999) concerning the chemical-physical aspects.
The use of w/o microemulsions as vehicles to obtain a controlled release of active ingredients which are hydrophilic or are made hydrophilic by suitable derivatization, is reported in the patent literature.
In particular, as for biodegradable molecules such as peptides, the parenteral administration of w/o microemulsions containing said active ingredients is reported in a study [M.R.Gasco et al., Int.J.Pharm., 62, 119 (1990)] wherein an LHRH hormone analog, formulated in a microemulsion consisting of components considered biocompatible and containing 500 μg/ml of the active ingredient, administered by single intramuscular injection at doses of 3 mg/Kg in adult male rats weighing about 200 g, decreased testosterone plasma levels for a time up to about 30 days after the injection; said levels were lower than those observed in a second group of mice treated with repeated injections (one a day for 28 days) at doses of 100 μg/Kg of active ingredient in buffer solution. It should however be noted that the decrease in the testosterone concentration was not homogeneous in time during observation, and it became therapeutically effective only 8 days after the administration.
This delay in the therapeutical effect is not very advantageous,
particularly in the treatment of prostate tumor which is known to require testosterone for growing; therefore the faster the testosterone normal production is stopped, the more effective the treatment.
The above mentioned paper shows the effectiveness of a w/o microemulsion consisting of ethyl oleate (60.5%), water (10.1%), phosphatidyl choline (18.9%) and caproic acid (10.5%) for the sustained release of the peptide. The surfactant (phosphatidylcholine) to co-surfactant (caproic acid) ratio is 1.8. The components of said microemulsion, individually taken, are considered biologically compatible by the Authors. No mention is made of the biocompatibility of the microemulsion as a whole neither of the condition of the subcutaneous tissue in contact with the formulation.
According to the teaching of said paper, a w/o microemulsion containing Leuprolide acetate as active ingredient with LHRH activity was prepared, consisting of ethyl oleate (66.9%), water (9.7%), phosphatidyl choline (19.4%) and a caproic acid/butyric acid 3/1 mixture (3.9%). According to this paper, the mixture with butyric acid was used instead of caproic acid alone in order to minimize the surfactant to co-surfactant ratio, which is in this case 4.9 instead of 1.8. The in vivo test carried out by subcutaneous injection of the product in the rat has confirmed the effectiveness but has also surprisingly shown alarming local ulcerogenicity and persistent formation of subcutaneous granulomas. This pharmacologically unacceptable result, notwithstanding the lower amounts of co-surfactants used, proved that the biocompatibility of the single components of the microemulsion was not sufficient to ensure the biocompatibility of the mixture constituting the microemulsion, when used for the parenteral administration.
Similarly, the mixtures disclosed and claimed in various patents, e.g. WO 94/08610, although providing stable microemulsions and possible controlled releases of the active ingredient in time, do not teach to those skilled
in the art how to obtain the sustained release of an hydrophilic active ingredient while avoiding such side effects. Said microemulsions usually consist, in fact, of water, an oily component, a surfactant, a co- surfactant, and optionally electrolytes, in various ratios. Neither biocompatibility of the microemulsion "in toto" is evaluated, nor the necessary ratios of mixture components to active ingredient are indicated, to obtain stability of both the active ingredient and the microemulsion as well as biocompatibility of the formulation.
On the other hand, said patents did not specifically consider the problems concerning local tolerability connected with intramuscular (i.m.) and subcutaneous (s.c.) administrations, which are the most suitable and easy routes for the parenteral administration.
An alternative technology already used at the industrial level for the sustained release of peptides is that described and claimed in a number of patents, inter alia US 3,976,071, wherein such release is obtained by the use of bioerodible polymers in which the active ingredient is inbodyrated. Typical examples of bioerodible polymers are polymers based on glycolic acid and lactic acid. The drawback of said technology is that it is relatively expensive and troublesome compared with the above described microemulsions, furthermore it requires the use of organic, in particular chlorinated, solvents during the preparation, which involves problems in terms of environmental impact and safety of the pharmaceutical formulation.
On the other hand, said formulations advantageously cause not persistent granulomas and do not induce local ulcerogenicity. Disclosure of the invention The present invention aims at providing sustained release pharmaceutical compositions in the form of stable w/o microemulsions, which are easy to prepare, can be sterilized, are free from remarkable systemic or topical side effects, are suitable for parenterally administering, preferably i.m. or s.c,
active ingredients which are hydrophilic or are made hydrophilic through suitable derivatization, thereby obtaining a remarkable technical improvement compared with the known technique.
A procedure has been found, consisting in the clinical, post-mortem, and histological examinations of the animals treated with the above mentioned microemulsions, suitable for thoroughly evaluating the biocompatibility of any formulations for the sustained release administration.
According to this procedure, a microemulsion is considered acceptable, according to what stated in literature (Protein Formulation and Delivery - E.J.McKelly 2000 pages 245-247), when any local swelling, more or less marked depending on the administered dose, is anyway reversible; on the other hand, a similar tissular response is also observed for materials considered biodegradable, which response is apparently important in affecting the sustained release of the drug in time. A local intolerance in the form of persistent ulcerations is conversely considered unacceptable.
The microemulsions of the present invention consists for up to 20% of an internal hydrophilic aqueous phase containing the active ingredient, for 30 to 98% of a hydrophobic external phase and for up to 50% of a surfactant alone or in admixture with a co-surfactant. The microemulsion preferably contains a percentage < 35% of surfactant and co-surfactant, with a surfactant/co- surfactant ratio > 2, and most preferably > 3,5.
Other biologically compatible excipients which do not affect the stability of the microemulsion can also be present.
Suitable surfactants for the microemulsions of the invention are selected from natural or synthetic glycerophospholipids containing residues of C4-C20 saturated or unsaturated carboxylic acids, having as phosphoester moiety a residue of choline, ethanolamine, serine, glycerol; cholesterol; C12-C20 fatty acid esters of sugars such as sorbitol, galactose, glucose, saccharose;
polyoxyethylene sorbitan C12-C2o fatty acid esters.
The optionally present co-surfactants are selected from C8-C2o fatty acids, C2-C14 polyhydroxyalkanes, particularly propylene glycol, hexanediol and glycerol, C2-C12 alcohols, esters of lactic acid with a C2-C8 alcohol residue. The hydrophobic continuous phase is selected from the following compounds, alone or in mixture: esters of Cg-C2o saturated or unsaturated carboxylic acids with a C2-C8 alcohol residue or mono, di- and triglycerids of C8-C2o fatty acids, or vegetable oils suitable for the parenteral administration, such as soybean, peanut, sesame, cottonseed, sunflower oils. The microemulsions of the invention are further characterized by pH ranging from 4.5 to 7.5, preferably from 5 to 7, said pH, when not intrinsic to the composition of the microemulsion, being preferably obtained by addition of a suitable amount of a natural amino acid to the microemulsion without affecting its stability and the average size of the droplets. The w/o microemulsions of the invention are particularly suitable as carriers for peptides, in particular LHRH analogs such as Leuprolide acetate, Goserelin, Triptorelin, Nafarelin acetate, Histrelin, Cetrorelix or the corresponding acetates, or peptides such as Somatostatin or its analogs such as Octreotide and Lanreotide acetate. Furthermore, the microemulsions of the invention are particularly suitable as carriers for polysaccharides, in particular unfractioned heparin or low molecular weight heparins.
The microemulsions of the invention allow to prepare formulations with sustained release of hydrophilic active ingredients. Said sustained release formulations, which are a further object of the invention, induce no local ulcerogenicity and produce non persistent granulomas, which are reabsorbed during the time in which the medicament is effective. In the case of LHRH-type peptides, and in particular Leuprolide, Goserelin, Triptorelin, Nafarelin acetate,
Histrelin, Cetrorelix and the corresponding acetates, sustained release for at least 30 days can be obtained. In the case of Somatostatin, Octreotide and Lanreotide, sustained release for at least 8 days can be obtained.
The invention further relates to the use of a microemulsion according to the invention comprising Leuprolide, Goserelin, Triptorelin, Nafarelin acetate, Histrelin, Cetrorelix or the corresponding acetates for the preparation of a medicament for suppressing testosterone production after single administration for at least 30 days, where testosterone level already decreases 48 h after the administration. The invention also relates to the use of the microemulsions containing
Octreotide or its analogues for the preparation of a medicament for suppressing growth hormone production for at least 8 days.
A further object of the present invention is the use of the microemulsions containing unfractioned heparin or low molecular weight heparins for the preparation of sustained release medicaments upon single administration.
The following examples further illustrate the present invention. Example 1 - Preparation of a w/o microemulsion containing Leuprolide acetate a) Preparation of the aqueous phase 350 mg of Leuprolide acetate are dissolved in 10 ml of water for injections added with 200 mg of lysine. b) Preparation of the oily phase
60 g of ethyl oleate, 25 g of soy lecithin (purity >95%) and 5 g of caprylic acid are mixed separately, in a suitable vessel thermostatized at a temperature of 60-70°C, under stirring. The resulting clear homogeneous solution is cooled at room temperature. c) Preparation of the microemulsion
The aqueous phase (solution a) is added to the oily phase (solution b)
under stirring, to obtain an optically transparent, homogeneous microemulsion. A pH value of about 6 was evaluated based on the used amounts of lysine and caprylic acid fraction soluble in the aqueous phase.
Said microemulsion is sterile filtered through a suitable 0.22 μm membrane.
The Leuprolide acetate content of said microemulsion was evaluated by HPLC analysis in the following conditions:
Stationary phase: Vydac C18 5μ column (250 x 4 mm)
Mobile phase A: H20 + 0.1% TFA B: CH3OH + 0.1% TFA
Gradient: 20' 100% A to 100% B
Flow: 0.8 ml/min
Detector: UV 214 nm
The content in Leuprolide acetate is 3 mg/ml. Example 2 - Preparation of a w/o microemulsion containing Leuprolide acetate
The procedure of Example 1 is followed, but solubilizing 600 mg of Leuprolide acetate in 10 ml of water.
Example 3 - Preparation of a w/o microemulsion containing Leuprolide acetate
The procedure of Example 1 is followed, but without adding 200 mg of lysine. Calculated pH is about 3.
Example 4 - Preparation of a w/o microemulsion containing Leuprolide acetate The procedure of Example 1 is followed, but solubilizing 900 mg of
Leuprolide acetate in 10 ml of water.
Example 5 - Preparation of a w/o microemulsion containing Leuprolide acetate
The procedure of Example 1 is followed, but changing the amounts of surfactant and co-surfactant to 15 g of soy lecithin and 3 g of caprylic acid, respectively. In this way, although keeping the ratio between the two components unchanged (5: 1) the total amount of the surfactant/co-surfactant mixture is changed from 30 % to 18%.
Example 6 - Preparation of a w/o microemulsion containing Octreotide
The procedure of Example 1 is followed, but solubilizing 3 g of Octreotide in 10 ml of water, instead of 350 mg of Leuprolide acetate in 10 ml of water. Example 7 - Preparation of a w/o microemulsion containing Heparin
The procedure of Example 1 is followed, but solubilizing in 10 ml of water 50 mg of unfractioned heparin in the form of calcium or sodium salt, instead of 350 mg of Leuprolide acetate.
Example 8 - Preparation of a w/o microemulsion containing Leuprolide acetate
The procedure of Example 1 is followed, but changing the quali- quantitative composition of the oily phase: ethyl oleate (66.9%), phosphatidyl choline (19.4%) and a 3: 1 caproic acid - butyric acid mixture (totally 3.9%). Example 9 - Preparation of a w/o microemulsion containing Leuprolide acetate a) Preparation of the aqueous phase
60 mg of Leuprolide acetate are dissolved in 0.6 ml of water for injections added with 8 mg of lysine. b) Preparation of the oily phase
2.1 g of ethyl oleate, 215 mg of polyoxyethylene sorbitan monooleate and 1 g of soy lecithin are mixed in a suitable vessel, heating at 50°C under stirring. The resulting clear homogeneous mixture is cooled at room temperature.
The aqueous solution is slowly added in portions to the oily mixture
under stirring, to obtain an optically clear microemulsion containing 1.5% of Leuprolide acetate.
Example 10 - Preparation of a w/o microemulsion containing Leuprolide acetate a) Preparation of the aqueous phase
60 mg of Leuprolide acetate are dissolved in 0.2 ml of water for injections added with 4.1 mg of lysine. b) Preparation of the oily phase
1.2 g of ethyl oleate, 0.5 g of poly oxy ethyl ene sorbitan monooleate and 0.1 g of caprylic acid are mixed in a suitable vessel, heating to 50°C under stirring. The resulting clear homogeneous mixture is cooled at room temperature.
The aqueous solution is slowly added in portions to the oily mixture under stirring, to obtain an optically clear microemulsion containing 3 mg/ml of Leuprolide acetate.
Example 11 - Preparation of a w/o microemulsion containing Octreotide acetate a) Preparation of the aqueous phase
20 mg of Octreotide acetate are dissolved in 0.2 ml of water for injections containing 0.2 g of propylene glycol and 4 mg of lysine. b) Preparation of the oily phase
0.98 g of ethyl oleate, 0.5 g of soy lecithin and 0.1 g of caprylic acid are mixed in a suitable vessel, heating to 50°C under stirring. The resulting clear homogeneous mixture is cooled at room temperature. The aqueous solution is slowly added in portions to the oily mixture under stirring. The resulting optically clear microemulsion contains 10 mg/ml of Octreotide acetate.
Example 12 - Preparation of a w/o microemulsion containing Octreotide acetate a) Preparation of the aqueous phase
10 mg of Octreotide acetate are dissolved in 0.1 ml of water for injections added with 2 mg of lysine. b) Preparation of the oily phase
0.59 g of ethyl oleate, 0.25 g of soy lecithin and 0.05 g of caprylic acid are mixed in a suitable vessel, heating to 50°C under stirring. The resulting clear homogeneous mixture is cooled at room temperature. The aqueous solution is slowly added in portions to the oily mixture under stirring. The resulting optically clear microemulsion contains 1% of Octreotide acetate.
Example 13 - Preparation of a w/o microemulsion containing Octreotide acetate 0.59 g of ethyl oleate, 0.25 g of soy lecithin and 0.05 g of caprylic acid are mixed in a suitable vessel, heating to 50°C under stirring. The resulting clear homogeneous mixture is cooled at room temperature. 0.1 g of water for injections containing 2 mg of lysine, are gradually added under stirring to the oily solution. The resulting optically clear microemulsion is added under stirring with 10 mg of Octreotide acetate. The active ingredient is inbodyrated in said microemulsion within a few seconds. The microemulsion is filtered through a 0.22 mem polysulfone filter. The resulting .optically clear microemulsion, analyzed by HPLC, shows a content in Octreotide acetate of 6.35 mg/ml. Example 14 - Preparation of a w/o microemulsion containing Myoglobin a) Preparation of the aqueous phase
5.5 mg of Myoglobin are dissolved in 1.5 ml of water for injections added with 10 mg of lysine.
b) Preparation of the oily phase
2 g of ethyl oleate, 1.2 g of soy lecithin and 0.25 g of caprylic acid are mixed, in a suitable vessel, heating to 50°C. The resulting clear homogeneous mixture is cooled at room temperature. The aqueous solution is slowly added in portions to the oily mixture under stirring. The resulting optically clear microemulsion contains 1.3 mg/ml of Myoglobin.
Example 15 - In vivo evaluation of the effectiveness of the microemulsion containing Leuprolide acetate prepared as described in Examples 1 and 2. Three groups of Sprague Dawley male rats (10 per each group) were housed for 5 days with water and food ad libitum before treatment.
Two microemulsion formulations prepared as described in Examples 1 and 2, with different concentrations of Leuprolide acetate, namely 3 mg/ml (Example 1) and 6 mg/ml (Example 2) were administered in a single dose, each in a group of rats, at the dose of active corresponding to 0.750 mg/kg.
Control animals (3 per group) received saline solution.
Testosterone plasma levels after taking the blood samples were evaluated at days 1, 2, 3, 4, 7, 14, 21, 28, 42 and 56. Blood samples were centrifuged and serum testosterone was measured by EIA kit. Serum testosterone levels were evaluated until 60 days after administration.
The results are described in Figure 1.
The following Table 1 summarizes the data concerning organs weight in the treated animals.
Table 1 - Effect of the microemulsions prepared as described in Examples 1 and 2 on body and reproductive organs weight in rats.
Microemulsion Body and reproductive organs weight (g) after 28 and 56 days
Data expressed as mean + standard error of the group (5 animals)
* ρ<0.001; 0 p<0.01; # p<0.05 vs. saline (ANOVA test and Bonferroni f test for multiple comparisons).
The formulations of the present invention, independently on the concentration of the active in the microemulsion, are free from substantial systemic or local side effects and provide the sustained release of the active ingredient for a duration of at least 30 days and therapeutic efficacy already 48 h after the injection.
The efficacy is comparable to that obtainable when using the commercial depot formulation "Enantone" based on bioerodible polymers. Example 16 - Evaluation of the subcutaneous tolerability of the microemulsions The test for the evaluation of the subcutaneous tolerability was effected by injecting groups of at least 9 rats with a single administration of the microemulsions reported in the following Table 2.
Clinical, post-mortem and histologic examinations were carried out 48h, 7 days and 14 days after the administration. Table 2
(1) Microemulsion prepared as described in Example 1.
(2) Microemulsion prepared as described in Example 8. * disclosure of the score: 1 slight effect; 2 moderate; 3 severe.
This test considers biologically compatible the formulations which induce no persistent local ulcerations, whereas the presence of swelling is a
function of the amount of product injected and of the rate of elimination of the ethyl oleate from subcutaneous tissues, as described by Howard et al. in Int. J. Pharm. 16 (1983) 31-39.
Example 17 - In vivo evaluation of the effectiveness of the microemulsion containing Octreotide acetate
A dose corresponding to 6 mg/rat of microemulsion containing
Octreotide prepared as described in Example 11 was administered to 6 male rats weighing about 175-200 g. Plasma samples were taken before the administration of the compound and 0.5 hours, 24 hours, 4, 6 and 8 days after treatment.
Octreotide was extracted from plasma and analyzed with LC-MS-MS apparatus vs. a calibration curve. Plasma levels are reported in the following table 3 :
Table 3
Significant Octreotide plasma levels were found until 8 days after treatment.
Example 18 - Evaluation of the dose/efficacy ratio of the microemulsion containing Leuprolide acetate The formulation containing Leuprolide acetate, prepared as described in
Example 2, was administered to rats, in a single dose of 2.25 mg/kg (Example).
Control animals received a corresponding dose of saline solution (Control).
Testosterone plasma levels on blood samples were evaluated at days 0, 1,
2, 3, 5, 7, 14, 21, 28, 42 and 56. Blood samples were centrifuged and serum testosterone was measured by an Elisa kit. Results are shown in Figure 2.
The data concerning organs weights in treated animals are summarized in the following Table 4.
Table 4: Effect of a Leuprolide acetate microemulsion or of a saline solution on the body and reproductive organs weight in rats (Example and Control).
Body and reproductive organs weight (g) on 56 day
Body Testes Prostate Seminal vesicles
Control 645 + 34 3.73 + 0.16 0.82 + 0.04 1.96 + 0.09
1.94 + 0.42 0.35 + 0.14 0.55 + 0.16 Example 608 + 35 (pO.Ol) (p<0.5) (p<0.05)
Reduction of both testosterone plasma levels and reproductive organs weight is clearly evidenced 56 days after the administration of the microemulsion.
Claims (20)
1. A stable, biologically compatible, well tolerated w/o microemulsion, suitable for the parenteral administration of biologically active compounds which are hydrophilic or are made hydrophilic by suitable derivatization, providing the sustained release of the active compounds contained therein.
2. A w/o microemulsion as claimed in claim 1 characterized in that, after administration to experiment animals, it induces no persistent ulcerations, any swelling at the injection site being reversible.
3. A microemulsion as claimed in claim 1 or 2, wherein the hydrophilic, biologically active compounds are peptides, proteins, oligo- or polysaccharides.
4. A microemulsion as claimed in claim 3, wherein the biologically active compound is a peptide.
5. A microemulsion as claimed in claim 4, wherein the biologically active compound is a LHRH hormone peptide analog.
6. A microemulsion as claimed in claim 5, wherein the biologically active compound is Leuprolide acetate, Goserelin, Triptorelin, Nafarelin, Histrelin, Cetrorelix or the corresponding acetates.
7. A microemulsion as claimed in claims 5 or 6, which provides the sustained release of the active compound for at least 30 days.
8. A microemulsion as claimed in claim 4, wherein the biologically active compound is Somatostatin, Octreotide or Lanreotide.
9. A formulation as claimed in claim 8, which provides the sustained release of the peptides for at least 8 days.
10. A microemulsion as claimed in claim 3, wherein the biologically active compound is an oligo- or polysaccharide.
11. A microemulsion as claimed in claim 10, wherein the biologically active compound is unfractioned heparin or low molecular weight heparins.
12. A w/o microemulsion as claimed in any one of the preceding claims, consisting of: a) up to 20% of an internal hydrophilic aqueous phase containing the therapeutically active hydrophilic compound; b) for 30 to 98% of a hydrophobic external phase; c) for up to 50% of a surfactant alone or in admixture with a co-surfactant.
13. A microemulsion as claimed in claim 12, wherein the surfactant is selected from the group consisting of: a) natural or synthetic glycerophospholipids containing residues of C4-C20 saturated or unsaturated carboxylic acids, having as phosphoester moiety a residue of choline, ethanolamine, serine, glycerol; b) cholesterol; c) sugars C12-C2o fatty acid esters; d) polyoxyethylene sorbitan C12-C2o fatty acid esters;
14. A microemulsion as claimed in claim 12 wherein the co-surfactant is selected from C8-C20 fatty acids; C2-C14 polyhydroxyalkanes; C2-C12 alcohols; esters of lactic acid with a C2-C8 alcohol residue.
15. A microemulsion as claimed in claim 12 wherein the hydrophobic continuous phase is selected from the following compounds, alone or in mixture: esters of C8-C2o saturated or unsaturated carboxylic acids with a C2-C8 alcohol residue or mono, di- and triglycerids of Cg-C2o fatty acids or vegetable oils suitable for the parenteral administration.
16. A microemulsion as claimed in claim 13, wherein the aqueous phase containing the biologically active compound has pH between 4.5 and 7.5, preferably between 5 and 7.
17. A microemulsion as claimed in claim 16, wherein pH is adjusted by addition of natural amino acids.
18. The use of a microemulsion as claimed in the preceding claims, comprising Leuprolide, Goserelin, Triptorelin, Nafarelin acetate, Histrelin, Cetrorelix or the corresponding acetates or other LHRH analogs for the preparation of a medicament for suppressing testosterone production after single administration for at least 30 days, where testosterone level already decreases 48 h after the administration.
19. The use of a microemulsion as claimed in the preceding claims, comprising Octreotide or its analogues for the preparation of a medicament for suppressing growth hormone production for at least 8 days.
20. The use of a microemulsion as claimed in the preceding claims containing unfractioned heparin or low molecular weight heparins for the preparation of medicaments with sustained release after single administration.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI200A001173 | 2000-05-26 | ||
| IT2000MI001173A IT1318539B1 (en) | 2000-05-26 | 2000-05-26 | PROLONGED RELEASE PHARMACEUTICAL COMPOSITIONS FOR THE PARENTERAL ADMINISTRATION OF BIOLOGICALLY HYDROPHILE SUBSTANCES |
| PCT/EP2001/005949 WO2001089479A2 (en) | 2000-05-26 | 2001-05-23 | Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2001281786A1 true AU2001281786A1 (en) | 2002-02-21 |
| AU2001281786B2 AU2001281786B2 (en) | 2005-07-21 |
| AU2001281786B8 AU2001281786B8 (en) | 2005-11-17 |
Family
ID=11445131
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001281786A Expired AU2001281786B8 (en) | 2000-05-26 | 2001-05-23 | Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| AU8178601A Pending AU8178601A (en) | 2000-05-26 | 2001-05-23 | Sustained release pharmaceutical compositions for the parenteral administration of biologically active hydrophilic compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU8178601A Pending AU8178601A (en) | 2000-05-26 | 2001-05-23 | Sustained release pharmaceutical compositions for the parenteral administration of biologically active hydrophilic compounds |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7157099B2 (en) |
| EP (1) | EP1283700B1 (en) |
| JP (1) | JP4954423B2 (en) |
| KR (1) | KR100802625B1 (en) |
| CN (1) | CN100479856C (en) |
| AT (1) | ATE321533T1 (en) |
| AU (2) | AU2001281786B8 (en) |
| BR (1) | BRPI0111016B8 (en) |
| CA (1) | CA2409854C (en) |
| CY (1) | CY1105262T1 (en) |
| CZ (1) | CZ302059B6 (en) |
| DE (1) | DE60118395T2 (en) |
| DK (1) | DK1283700T3 (en) |
| ES (1) | ES2257428T3 (en) |
| HR (1) | HRP20020929A2 (en) |
| HU (1) | HU228926B1 (en) |
| IL (1) | IL153011A0 (en) |
| IT (1) | IT1318539B1 (en) |
| MX (1) | MXPA02011539A (en) |
| NO (1) | NO334880B1 (en) |
| PL (1) | PL203354B1 (en) |
| PT (1) | PT1283700E (en) |
| RU (1) | RU2272615C2 (en) |
| SI (1) | SI1283700T1 (en) |
| SK (1) | SK16552002A3 (en) |
| WO (1) | WO2001089479A2 (en) |
| YU (1) | YU88202A (en) |
| ZA (1) | ZA200209520B (en) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| EP1787658B1 (en) | 2005-11-10 | 2012-03-14 | CHEMI S.p.A. | Sustained release formulations of somatostatin analogue inhibitors of growth hormone |
| BRPI0710503A2 (en) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | use of a pharmaceutical composition, pharmaceutical composition, and oral dosage form |
| KR100816065B1 (en) * | 2006-11-27 | 2008-03-24 | 동국제약 주식회사 | Preparation method of sustained-release microcapsules having good initial burst inhibiting property and the microcapsules thereby |
| RU2362544C2 (en) * | 2007-04-09 | 2009-07-27 | Закрытое акционерное общество "Санкт-Петербургский институт фармации" | Nano emulsion with biologically active substances |
| EP2207427B1 (en) * | 2007-10-04 | 2017-05-03 | Medical Instill Technologies, Inc. | Apparatus and method for formulating and aseptically filling liquid products |
| KR20110007242A (en) | 2008-05-07 | 2011-01-21 | 메리온 리서치 Ⅲ 리미티드 | Compositions of peptides and processes of preparation thereof |
| TW201600108A (en) | 2010-01-13 | 2016-01-01 | 艾普森藥品公司 | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
| US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
| JP2013523162A (en) | 2010-04-06 | 2013-06-17 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Compositions and methods for inhibiting the expression of the CD274 / PD-L1 gene |
| EP3456827A3 (en) | 2010-06-02 | 2019-05-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| WO2012028733A1 (en) | 2010-09-03 | 2012-03-08 | Novagali Pharma Sa | A water-in-oil type emulsion for treating a disease of the eye |
| US9107822B2 (en) | 2010-09-03 | 2015-08-18 | Santen Sas | Water-in oil type emulsion for treating a disease of the eye |
| SI2425814T1 (en) | 2010-09-03 | 2013-10-30 | Novagali Pharma S.A. | A water-in-oil type emulsion for treating a disease of the eye |
| EP2648763A4 (en) | 2010-12-10 | 2014-05-14 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
| US9193973B2 (en) | 2010-12-10 | 2015-11-24 | Alynylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (EPO) production |
| EP2661273A4 (en) | 2011-01-07 | 2014-06-04 | Merrion Res Iii Ltd | Pharmaceutical compositions of iron for oral administration |
| CA2831284C (en) | 2011-03-29 | 2023-12-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of tmprss6 gene |
| EP3354343B1 (en) | 2011-06-02 | 2023-09-06 | President and Fellows of Harvard College | Methods and uses for ex vivo tissue culture systems |
| SG10201800715PA (en) | 2011-06-21 | 2018-02-27 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof |
| EP3564393A1 (en) | 2011-06-21 | 2019-11-06 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
| WO2012178033A2 (en) | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
| JP2014527036A (en) | 2011-06-27 | 2014-10-09 | ザ ジャクソン ラボラトリー | Methods and compositions for the treatment of cancer and autoimmune diseases |
| JP2014526887A (en) | 2011-08-01 | 2014-10-09 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | How to improve the success rate of hematopoietic stem cell transplantation |
| CN102552187B (en) * | 2012-02-28 | 2015-10-28 | 大连医科大学 | Oral hydroxyl silk peptide nanoparticles and preparation method thereof |
| CN102552138A (en) * | 2012-02-28 | 2012-07-11 | 大连医科大学 | Oral W/O microemulsion preparation of cyclo-trans-4-hydroxyprolyl-L-serine and preparation method of same |
| CA2866262C (en) * | 2012-03-05 | 2020-06-16 | Archer Daniels Midland Company | Microemulsions and uses thereof as delivery systems |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| KR102096014B1 (en) | 2012-12-05 | 2020-04-03 | 알닐람 파마슈티칼스 인코포레이티드 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| ES2649490T3 (en) | 2013-03-14 | 2018-01-12 | Alnylam Pharmaceuticals, Inc. | Compositions of RNAi against component C5 of the complement and methods for its use |
| WO2014160871A2 (en) | 2013-03-27 | 2014-10-02 | The General Hospital Corporation | Methods and agents for treating alzheimer's disease |
| AR096203A1 (en) | 2013-05-06 | 2015-12-16 | Alnylam Pharmaceuticals Inc | DOSAGES AND METHODS FOR MANAGING NUCLEIC ACID MOLECULES FORMULATED IN LIPIDS |
| UY35582A (en) | 2013-05-22 | 2014-10-31 | Alnylam Pharmaceuticals Inc | COMPOSITIONS OF ARNi DE SERPINA1 AND ITS METHODS OF USE |
| SG11201510565TA (en) | 2013-05-22 | 2016-01-28 | Alnylam Pharmaceuticals Inc | Tmprss6 irna compositions and methods of use thereof |
| AU2014278011B2 (en) | 2013-06-14 | 2020-03-19 | Alyssum Therapeutics, Inc. | Lipid-based platinum compounds and nanoparticles |
| EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| EP2832361A1 (en) * | 2013-07-29 | 2015-02-04 | Ipsen Pharma S.A.S. | Aqueous sustained release compositions of LHRH analogs |
| EP3052626A1 (en) | 2013-10-02 | 2016-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| NZ757749A (en) | 2013-10-04 | 2022-07-01 | Icahn School Med Mount Sinai | Compositions and methods for inhibiting expression of the alas1 gene |
| BR112016013148B1 (en) | 2013-12-12 | 2024-02-27 | Alnylam Pharmaceuticals, Inc | DOUBLE-STANNED RIBONUCLEIC ACID (dsRNA) FOR INHIBITING THE EXPRESSION OF COMPLEMENT FACTOR B (CFB) IN A CELL, PHARMACEUTICAL COMPOSITION FOR INHIBITING THE EXPRESSION OF A COMPLEMENT FACTOR B GENE, ITS USE, AND IN VITRO METHOD OF INHIBITING EXPRESSION COMPLEMENT FACTOR B (CFB) IN A CELL |
| JP6594902B2 (en) | 2014-02-11 | 2019-10-23 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Keto hexokinase (KHK) iRNA compositions and methods of use thereof |
| WO2015175510A1 (en) | 2014-05-12 | 2015-11-19 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
| US10238749B2 (en) | 2014-05-22 | 2019-03-26 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (AGT) iRNA compositions and methods of use thereof |
| KR101686986B1 (en) | 2014-07-28 | 2016-12-16 | 에스케이케미칼주식회사 | Immediate-release and sustained-release pharmaceutical compositon comprising leuprolide |
| EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| JOP20200115A1 (en) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression |
| EP3207138B1 (en) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
| WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
| JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| CN107250362B (en) | 2014-11-17 | 2021-10-22 | 阿尔尼拉姆医药品有限公司 | Apolipoprotein C3(APOC3) iRNA compositions and methods of use thereof |
| TW201702218A (en) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
| US11400139B2 (en) | 2015-01-20 | 2022-08-02 | The Children's Medical Center Corporation | Anti-NET compounds for treating and preventing fibrosis and for facilitating wound healing |
| US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| EP3256587A2 (en) | 2015-02-13 | 2017-12-20 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| WO2016164746A1 (en) | 2015-04-08 | 2016-10-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| EP3283631A1 (en) | 2015-04-13 | 2018-02-21 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| EP3292201A2 (en) | 2015-05-06 | 2018-03-14 | Alnylam Pharmaceuticals, Inc. | Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof |
| EP4365291A3 (en) | 2015-06-12 | 2024-08-14 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
| US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
| EP3344769B1 (en) | 2015-09-02 | 2024-04-17 | Alnylam Pharmaceuticals, Inc. | Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof |
| TW201718857A (en) | 2015-09-14 | 2017-06-01 | 艾爾妮蘭製藥公司 | Compositions and methods for inhibiting expression of the ALAS1 gene |
| WO2017048620A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| WO2017064657A1 (en) | 2015-10-16 | 2017-04-20 | Invictus Oncology Pvt. Ltd. | Fluorescent anticancer platinum drugs |
| CA3007014A1 (en) | 2015-12-07 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
| WO2017100542A1 (en) | 2015-12-10 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof |
| MA45295A (en) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP / VIGILINE) RNA COMPOSITION AND METHODS FOR USING THEM |
| JP2019518028A (en) | 2016-06-10 | 2019-06-27 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Complement component C5i RNA composition and its use for treating paroxysmal nocturnal hemoglobinuria (PNH) |
| TW202313978A (en) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | Serpina1 irna compositions and methods of use thereof |
| US20190350962A1 (en) | 2016-12-16 | 2019-11-21 | Alnylam Pharmaceuticals, Inc. | METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS |
| CA3069868A1 (en) | 2017-07-13 | 2019-01-17 | Alnylam Pharmaceuticals Inc. | Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof |
| CA3078971A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| EP3710587A1 (en) | 2017-11-16 | 2020-09-23 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
| WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
| AU2018388484A1 (en) | 2017-12-18 | 2020-07-30 | Alnylam Pharmaceuticals, Inc. | High mobility group box-1 (HMGB1) iRNA compositions and methods of use thereof |
| AR115960A1 (en) | 2018-08-16 | 2021-03-17 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF THE LECT2 GENE |
| CN118667811A (en) | 2018-09-18 | 2024-09-20 | 阿尔尼拉姆医药品有限公司 | Ketohexokinase (KHK) iRNA compositions and methods of use thereof |
| US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
| WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| US20220290152A1 (en) | 2019-09-03 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| EP4038189A1 (en) | 2019-10-04 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
| AU2020376840A1 (en) | 2019-11-01 | 2022-04-07 | Alnylam Pharmaceuticals, Inc. | Huntingtin (HTT) iRNA agent compositions and methods of use thereof |
| EP4051796A1 (en) | 2019-11-01 | 2022-09-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
| JP2023506181A (en) | 2019-12-13 | 2023-02-15 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Human chromosome 9 open reading frame 72 (C9ORF72) iRNA agent compositions and methods of use thereof |
| WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| AU2021220765A1 (en) | 2020-02-10 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing VEGF-A expression |
| EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
| WO2021188611A1 (en) | 2020-03-18 | 2021-09-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
| JP2023519274A (en) | 2020-03-26 | 2023-05-10 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | CORONAVIRUS iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
| TW202204618A (en) | 2020-04-06 | 2022-02-01 | 美商艾爾妮蘭製藥公司 | Compositions and methods for silencing myoc expression |
| WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
| WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| TW202204617A (en) | 2020-04-07 | 2022-02-01 | 美商艾爾妮蘭製藥公司 | Compositions and methods for silencing scn9a expression |
| AU2021263554A1 (en) | 2020-04-27 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein E (APOE) iRNA agent compositions and methods of use thereof |
| WO2021237097A1 (en) | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
| EP4162050A1 (en) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
| WO2022066847A1 (en) | 2020-09-24 | 2022-03-31 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
| WO2022076291A1 (en) | 2020-10-05 | 2022-04-14 | Alnylam Pharmaceuticals, Inc. | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
| AU2021365822A1 (en) | 2020-10-21 | 2023-06-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
| WO2022087329A1 (en) | 2020-10-23 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
| WO2022119873A1 (en) | 2020-12-01 | 2022-06-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| AU2022220704A1 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| CN117222739A (en) | 2021-02-25 | 2023-12-12 | 阿尔尼拉姆医药品有限公司 | Prion protein (PRNP) IRNA compositions and methods of use thereof |
| WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
| BR112023019981A2 (en) | 2021-03-29 | 2023-12-12 | Alnylam Pharmaceuticals Inc | COMPOSITIONS OF HUNTINGTINA IRNA AGENT (HTT) AND METHODS OF USE THEREOF |
| US20240180865A1 (en) * | 2021-04-08 | 2024-06-06 | Tionlab Therapeutics | Sustained-release lipid pre-concentrate |
| WO2022245583A1 (en) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
| KR20240017911A (en) | 2021-06-04 | 2024-02-08 | 알닐람 파마슈티칼스 인코포레이티드 | Human chromosome 9 open reading frame 72 (C9orf72) iRNA preparation composition and method of using the same |
| TW202333748A (en) | 2021-07-19 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
| TW202334418A (en) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | Huntingtin (htt) irna agent compositions and methods of use thereof |
| WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
| WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08505367A (en) * | 1992-10-16 | 1996-06-11 | スミスクライン・ビーチャム・コーポレイション | Pharmaceutical emulsion composition |
| SE512663C2 (en) * | 1997-10-23 | 2000-04-17 | Biogram Ab | Active substance encapsulation process in a biodegradable polymer |
| WO1999021533A2 (en) * | 1997-10-24 | 1999-05-06 | Neorx Corporation | Delivery vehicles for bioactive agents and uses thereof |
-
2000
- 2000-05-26 IT IT2000MI001173A patent/IT1318539B1/en active
-
2001
- 2001-05-23 MX MXPA02011539A patent/MXPA02011539A/en active IP Right Grant
- 2001-05-23 IL IL15301101A patent/IL153011A0/en active IP Right Grant
- 2001-05-23 JP JP2001585724A patent/JP4954423B2/en not_active Expired - Lifetime
- 2001-05-23 PL PL359601A patent/PL203354B1/en unknown
- 2001-05-23 AU AU2001281786A patent/AU2001281786B8/en not_active Expired
- 2001-05-23 BR BR0111016-0 patent/BRPI0111016B8/en not_active IP Right Cessation
- 2001-05-23 EP EP01960242A patent/EP1283700B1/en not_active Expired - Lifetime
- 2001-05-23 CA CA2409854A patent/CA2409854C/en not_active Expired - Lifetime
- 2001-05-23 ES ES01960242T patent/ES2257428T3/en not_active Expired - Lifetime
- 2001-05-23 RU RU2002135086/15A patent/RU2272615C2/en active
- 2001-05-23 SK SK1655-2002A patent/SK16552002A3/en unknown
- 2001-05-23 PT PT01960242T patent/PT1283700E/en unknown
- 2001-05-23 SI SI200130529T patent/SI1283700T1/en unknown
- 2001-05-23 AT AT01960242T patent/ATE321533T1/en active
- 2001-05-23 AU AU8178601A patent/AU8178601A/en active Pending
- 2001-05-23 CN CNB018099254A patent/CN100479856C/en not_active Expired - Lifetime
- 2001-05-23 YU YU88202A patent/YU88202A/en unknown
- 2001-05-23 DK DK01960242T patent/DK1283700T3/en active
- 2001-05-23 US US10/258,616 patent/US7157099B2/en not_active Expired - Lifetime
- 2001-05-23 CZ CZ20023772A patent/CZ302059B6/en not_active IP Right Cessation
- 2001-05-23 KR KR1020027015828A patent/KR100802625B1/en active IP Right Grant
- 2001-05-23 WO PCT/EP2001/005949 patent/WO2001089479A2/en active IP Right Grant
- 2001-05-23 HU HU0301921A patent/HU228926B1/en unknown
- 2001-05-23 DE DE60118395T patent/DE60118395T2/en not_active Expired - Lifetime
-
2002
- 2002-11-22 HR HR20020929A patent/HRP20020929A2/en not_active Application Discontinuation
- 2002-11-22 ZA ZA200209520A patent/ZA200209520B/en unknown
- 2002-11-22 NO NO20025621A patent/NO334880B1/en not_active IP Right Cessation
-
2006
- 2006-06-05 CY CY20061100724T patent/CY1105262T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2409854C (en) | Sustained release pharmaceutical compositions for the parenteral administration of biologically active hydrophilic compounds | |
| AU2001281786A1 (en) | Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds | |
| DK1682091T3 (en) | COMPOSITIONS OF LIPIDS AND CATIONIC PEPTIDES | |
| KR101494594B1 (en) | Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same | |
| KR100220546B1 (en) | Lipophilic carrier preparations | |
| KR101586791B1 (en) | Sustained-release lipid pre-concentrate of GnRH analogues and pharmaceutical composition comprising the same | |
| JP2001508773A (en) | Sustained release composition | |
| US20040147578A1 (en) | Use of lipoaminoacids as absorption promoters in a pharmaceutical composition | |
| JP4426749B2 (en) | O / W emulsion formulation | |
| JPH08507065A (en) | Microemulsion containing pharmaceutical composition | |
| MXPA00010497A (en) | Pharmaceutical compositions capable of being gelled |